Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1–2 dose-confirmation study

Kristina M. Brooks, Patricia M. Flynn, Lauren Ziemba et al.|The Lancet HIV|2023

Cited by 13